Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Lewy Body Disease 1Congenital Hyperinsulinism 1Brain Neoplasms 1

Interventions

3-Iodobenzylguanidine 7gallium Ga 68 dotatate 4fluorodopa F 18 3pegfilgrastim 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 23-fluorobenzylguanidine 2tipifarnib 1pertuzumab 1pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1entrectinib 1cixutumumab 1arginyllysine 1Whole Body Imaging 1Vorinostat 1Tretinoin 1Stem Cell Transplantation 1Potassium Iodide 1Nivolumab 1Leucovorin 1LY2940680 1Isotretinoin 1Furosemide 1Floxuridine 1Erlotinib Hydrochloride 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Furosemide × Endocrine × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡